Akorn Defaults On Loan Agreement After Sale Bid Falls Flat
Market ‘Uncertainties’ Impacted Sale Process, Company Says
Executive Summary
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
You may also be interested in...
Bankruptcy Court Gives Green Light To Akorn Sale
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.
Q2 Results: COVID-19 Kicks Akorn While It’s Down
Akorn’s second-quarter revenues fell by $58m, as it braces for a restructuring and sale process.
Beleaguered Akorn Files For Bankruptcy
Akorn and its subsidiaries in the US have gone ahead with a Chapter 11 bankruptcy filing, paving the way for an in-court sale of the business and bringing the curtain down for now on the story of one of the hottest generic injectable properties of the last decade.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: